Billiontoone (NASDAQ:BLLN) Insider Shan Riku Sakakibara Sells 8,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $125.00, for a total value of $1,000,000.00. Following the transaction, the insider directly owned 204,000 shares of the company’s stock, valued at $25,500,000. The trade was a 3.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $123.25 on Tuesday. The company has a 50 day moving average of $101.46 and a 200 day moving average of $89.09. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The stock has a market cap of $5.67 billion and a P/E ratio of 224.09. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $138.70.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The business’s revenue for the quarter was up 83.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BLLN has been the subject of several research analyst reports. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. raised their price target on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Guggenheim began coverage on Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price target for the company. Finally, BTIG Research cut their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Billiontoone presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rossby Financial LCC bought a new position in Billiontoone in the fourth quarter valued at $25,000. Wells Fargo & Company MN bought a new stake in Billiontoone during the fourth quarter worth about $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone in the 4th quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Billiontoone during the 4th quarter valued at about $82,000. Finally, Renaissance Capital LLC bought a new position in shares of Billiontoone during the 4th quarter valued at about $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.